Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5548MR)

This product GTTS-WQ5548MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5548MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1605MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ14718MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ14748MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ10116MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ6720MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ15530MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ924MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ4217MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW